CA2776563A1 - Immunoconjugues comprenant des peptides issus de poxvirus et des anticorps diriges contre des cellules presentatrices d'un antigene pour des vaccins contre les poxvirus a base desous-unite - Google Patents

Immunoconjugues comprenant des peptides issus de poxvirus et des anticorps diriges contre des cellules presentatrices d'un antigene pour des vaccins contre les poxvirus a base desous-unite Download PDF

Info

Publication number
CA2776563A1
CA2776563A1 CA2776563A CA2776563A CA2776563A1 CA 2776563 A1 CA2776563 A1 CA 2776563A1 CA 2776563 A CA2776563 A CA 2776563A CA 2776563 A CA2776563 A CA 2776563A CA 2776563 A1 CA2776563 A1 CA 2776563A1
Authority
CA
Canada
Prior art keywords
seq
antibody
immunoconjugate
poxvirus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2776563A
Other languages
English (en)
Inventor
Alice P. Taylor
Boby Makabi-Panzu
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Publication of CA2776563A1 publication Critical patent/CA2776563A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2776563A 2009-11-05 2010-10-29 Immunoconjugues comprenant des peptides issus de poxvirus et des anticorps diriges contre des cellules presentatrices d'un antigene pour des vaccins contre les poxvirus a base desous-unite Abandoned CA2776563A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US61/258,369 2009-11-05
US25872909P 2009-11-06 2009-11-06
US61/258,729 2009-11-06
US12/754,140 2010-04-05
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 2010-04-06
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
US61/378,059 2010-08-30
PCT/US2010/054668 WO2011056721A2 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Publications (1)

Publication Number Publication Date
CA2776563A1 true CA2776563A1 (fr) 2011-05-12

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2776563A Abandoned CA2776563A1 (fr) 2009-11-05 2010-10-29 Immunoconjugues comprenant des peptides issus de poxvirus et des anticorps diriges contre des cellules presentatrices d'un antigene pour des vaccins contre les poxvirus a base desous-unite

Country Status (6)

Country Link
EP (1) EP2496256A4 (fr)
CN (1) CN102573902A (fr)
AU (1) AU2010315432A1 (fr)
CA (1) CA2776563A1 (fr)
IN (1) IN2012DN02692A (fr)
WO (1) WO2011056721A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3138581T3 (en) 2011-03-17 2019-04-15 Univ Birmingham REDIRECTED IMMUNTERY
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150238632A1 (en) * 2012-09-18 2015-08-27 University Of Washington Through Its Center For Commercialization Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells
CA2971288A1 (fr) 2015-02-02 2016-08-11 The University Of Birmingham Complexes d'epitope de peptide de fragment de ciblage ayant une pluralite d'epitopes de lymphocyte t
AU2016358296B2 (en) 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN109187982B (zh) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 一种tlr类疫苗佐剂的筛选和鉴定方法
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
CN113347993A (zh) * 2018-10-22 2021-09-03 艾赛澳克莱克斯疗法有限责任公司 突变牛痘病毒及其用途
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (fr) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Polypeptide de fusion au vih
WO1996040941A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Anticorps chimeriques pour l'acheminement d'antigenes jusqu'a des cellules selectionnees du systeme immunitaire
CA2223577A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Anticorps chimeriques pour l'acheminement d'antigenes jusqu'a des cellules selectionnees du systeme immunitaire
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
CN102174108B (zh) 2002-03-01 2016-06-29 免疫医疗公司 内在化抗-cd74抗体和使用方法
US7432342B2 (en) * 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
BRPI0607486B8 (pt) * 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CA2604032C (fr) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
WO2006113927A2 (fr) * 2005-04-20 2006-10-26 University Of Washington Peptides de la vaccine immunogenes et procedes d'utilisation de ces peptides
CA2607056C (fr) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
AU2006330051B2 (en) * 2005-12-16 2011-08-18 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
JP5699362B2 (ja) * 2008-04-10 2015-04-08 アイビーシー ファーマスーティカルズ，インコーポレイテッド 薬物動態が改善された四量体サイトカインをドック・アンド・ロック（ｄｎｌ）技術により調製するためのモジュール法

Also Published As

Publication number Publication date
WO2011056721A2 (fr) 2011-05-12
IN2012DN02692A (fr) 2015-09-04
EP2496256A4 (fr) 2013-07-17
WO2011056721A3 (fr) 2011-10-13
AU2010315432A1 (en) 2012-04-12
CN102573902A (zh) 2012-07-11
EP2496256A2 (fr) 2012-09-12

Similar Documents

Publication Publication Date Title
US20110064754A1 (en) Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
CA2776563A1 (fr) Immunoconjugues comprenant des peptides issus de poxvirus et des anticorps diriges contre des cellules presentatrices d'un antigene pour des vaccins contre les poxvirus a base desous-unite
US8883160B2 (en) Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
ES2928718T3 (es) Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
CN110023336B (zh) 用于治疗表达密蛋白之癌症疾病的与密蛋白6或密蛋白18.2和cd3结合的双特异性三价抗体
CN106414500B (zh) 抗-wt1/hla双特异性抗体
US9623115B2 (en) Dock-and-Lock (DNL) Complexes for Disease Therapy
US8562988B2 (en) Strategies for improved cancer vaccines
ES2330017T3 (es) Ligandos de cd40 y peptidos de ctl para tratar tumores.
CN109195994A (zh) 针对cd137的新型双特异性多肽
JP7169298B2 (ja) ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用
CN112898432A (zh) 能结合CD32B和CD79b的双特异性单价Fc双抗体及其用途
BR112020021111A2 (pt) anticorpo multiespecífico, ácido nucleico e formulação farmacêutica
JP2023528017A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
CN113412123A (zh) 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
US9550838B2 (en) Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
WO2014039840A1 (fr) Compositions de vaccin contre le vih et procédés associés
KR20230008162A (ko) 암 및 감염성 질환에 대한 면역요법을 위한 융합 단백질
CA3177288A1 (fr) Polytherapie faisant intervenir des pbmc modifiees et un immunoconjugue
US20170088635A1 (en) Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
AU2008238215B2 (en) Ig-pConsensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease
CA2758390A1 (fr) Complexes dnl (« dock-and-lock ») ciblant une cellule souche
US12023368B2 (en) Immunoconjugates
WO2023076768A1 (fr) Polythérapies contre le cancer et les maladies infectieuses
WO2022161598A1 (fr) Anticorps ciblant largement des coronavirus et leurs utilisations

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20161031